Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

talazoparib MeSH Supplementary Concept Data 2025


MeSH Supplementary
talazoparib
Unique ID
C586365
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C586365
Entry Term(s)
BMN 673
BMN-673
BMN673
Talzenna
Pharm Action
Poly(ADP-ribose) Polymerase Inhibitors
Registry Numbers
9QHX048FRV
CAS Type 1 Name
3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-
Heading Mapped to
*Phthalazines
Frequency
173
Note
inhibits both PARP1 and PARP2; structure in first source
Source
Oncogene. 2013 Nov 21;32(47):5377-87.
Date of Entry
2014/02/12
Revision Date
2019/10/30
talazoparib Preferred
BMN 673 Narrower
Talzenna Related
page delivered in 0.005s